ICON Plc Goldman Sachs 28 th Annual Global

ICON Plc. Goldman Sachs 28 th Annual Global Healthcare Conference. Tuesday 12 th June 2007. 1

Forward Looking Statements Certain statements contained herein including, without limitation, statements containing the words “believes, ” “anticipates, ” “intends, ” “expects” and words of similar import, constitute forwardlooking statements concerning the Company's operations, performance, financial condition and prospects. Because such statements involve known and unknown risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 2

The Journey So Far 1990 • Revenues $0. 5 million • Operating Profits $0 m • Staff 5 2006 • Revenues $456 million • Operating Profits $48 m • EPS $1. 33 • Staff 4, 300 2007 Guidance 3 • Revenues $560 -$580 • Operating Profit $60 - $65 • EPS $1. 70 - $1. 80 • Staff 4, 800 – 5, 000

Global Full Service Clinical Development Revenue by Region 4 US 53% EU 40% ROW 7%

…. . and the customer base continues to diversify. Client Concentration 2005, 2006, Q 1 2007 5

Q 1 ‘ 07 Revenue Breakdown Revenue by Customer Segment 6 Revenue by Therapeutic Area

Market Environment 7

Strong Market Environment with. . . • Fundamental R&D Spending Growth Trend 6%- 8% p. a. ¯ Phase II / III pipelines strengthening • Increased Outsourcing ¯ Being accelerated by activity & funding in Biotech / Speciality ¯ Globalisation of clinical research ¯ Cost containment pressures ¯ ¯ Evidence that projects, where CROs are engaged, complete faster than “internal only” studies* Growth c. 15% p. a. since 2001* • Increasing Regulation 8 ¯ More patients/ more studies ¯ Post marketing surveillance *Source: Tufts Centre for Study of Drug Development

Strong Gross Business wins has led to… ICON Gross Business Wins - Last 10 Quarters ($ millions) 9

…leading to record Total Backlog levels. ($ millions) 10

From this backlog, coverage of next 4 quarters revenues is robust……. . % coverage of next 4 quarters forecast revenues Value of backlog forecast to be earned in next 4 quarters 11

Strategy 12

Core Strategy is Organic Growth, with acquisitions adding new services or scale. Capitalise on market fundamentals to drive organic growth in all business units. Expand geographic footprint to exploit globalisation. Pursue acquisitions to enhance depth and scale of current operations and to additional complementary services e. g. Phase I Bioanalytical / Biomarkers Therapeutic specialists Safety / Phase IV Patient Recruitment specialists Staffing Cross-sell services to grow sales and margin 13

Financial Performance 14

Recent Financial Performance ($ millions, except EPS; includes stock option expense) Q 1 ’ 07 Q 1 ’ 06 % Increase Net Revenue 136. 1 98. 5 38. 2% Direct Costs 78. 6 54. 7 31. 4% SG & A 38. 7 30. 3 27. 8% 4. 2 _____ 3. 5 _____ 20. 6% _____ 14. 7 10. 1 46% 12. 3 _____ 7. 5 _____ 62. 7% _____ 42 c 27 c 56% 29. 5 m 28. 2 m 4. 6% 963 707 36% D&A Operating Income Net Income EPS (Inc SFAS 123 R) Weighted Average no. of Shares (Inc SFAS 123 R) 15 Backlog

Net Revenue CAGR of 30% over 7 Years CA 16 0 3 R % G (E)

Improving Margins 17

Quarterly Operating margins have been improving…. 18 * Including SFAS 123 non cash stock compensation charge

Investment Case Summary • • • 19 Top Global Clinical CRO - #4 Outstanding record of growth Strong market fundamentals Excellent strategic position Strong balance sheet Margin expansion opportunity